随着中国医药企业创新力的不断提升,跨国药企与国内企业BD的进程,在2026年依然如火如荼。日前,先声药业发布公告,旗下附属公司1月26日与全球生物制药公司勃林格殷格翰签署独家授权许可协议,勃林格殷格翰将获得用于炎症性肠病的TL1A/IL-23p19双特异性抗体SIM0709在大中华区以外的全球独家权益。这场看似寻常的商业交易,实则是中国创新药从“跟随者”向“领跑者”蜕变的缩影,尤其在TL1A/IL...
Source Link随着中国医药企业创新力的不断提升,跨国药企与国内企业BD的进程,在2026年依然如火如荼。日前,先声药业发布公告,旗下附属公司1月26日与全球生物制药公司勃林格殷格翰签署独家授权许可协议,勃林格殷格翰将获得用于炎症性肠病的TL1A/IL-23p19双特异性抗体SIM0709在大中华区以外的全球独家权益。这场看似寻常的商业交易,实则是中国创新药从“跟随者”向“领跑者”蜕变的缩影,尤其在TL1A/IL...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.